The stock market has almost closed the books on the fiscal year (FY) 2024-25 without a single company getting listed through ...

Compass Pathways plc downgraded to Hold after mixed trial results. Explore upcoming catalysts in depression treatment and ...

Amgen Inc. (NASDAQ:AMGN) is one of the These 10 Stocks Took A Shocking Fall. Amgen Inc. extended its losing streak to a ...

Why are companies adding Bitcoin to their treasuries, and could it backfire? A deep dive into capital erosion risks and lessons from GBTC and 2008.

Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial ...

Elon Musk and his DOGE committee ran around chasing examples of "waste, fraud and abuse," much of it trivial. Meanwhile, they missed the gigantic white elephants sitting in the middle of the room.

Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell ...

Novo Nordisk ends Wegovy deal with Hims over legal issues, sending the stock tumbling. What happens next? Here's a look.

Ontrak CEO and executive chairman Terren Peizer called the case a “true miscarriage of justice from the get-go.” ...

Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock is a Hold.

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...